NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
about
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
NFATC1 activation by DNA hypom ...... can be inhibited by ibrutinib.
@en
NFATC1 activation by DNA hypom ...... can be inhibited by ibrutinib.
@nl
type
label
NFATC1 activation by DNA hypom ...... can be inhibited by ibrutinib.
@en
NFATC1 activation by DNA hypom ...... can be inhibited by ibrutinib.
@nl
prefLabel
NFATC1 activation by DNA hypom ...... can be inhibited by ibrutinib.
@en
NFATC1 activation by DNA hypom ...... can be inhibited by ibrutinib.
@nl
P2093
P2860
P50
P356
P1476
NFATC1 activation by DNA hypom ...... can be inhibited by ibrutinib.
@en
P2093
Angela Garding
Anja Weigel
Arefeh Rouhi
Barbara Eichhorst
Christine Wolf
Christoph Plass
Daniel Mertens
Dieter Weichenhan
Florian Kuchenbauer
Jasmin Bahlo
P2860
P304
P356
10.1002/IJC.31057
P577
2017-09-18T00:00:00Z